Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is a promising biotech company that is focused on developing cutting-edge gene and cell therapies for various retinal diseases. The company's modifier gene therapy platform has shown promising results in clinical trials, with a 31% reduction in GA lesion area and a 27% reduction in EZ loss compared to controls. Ocugen also has potential for accelerated approval in the EU due to its impact on EZ loss, a strong indicator of visual acuity. The company is well-positioned for success with two ongoing pivotal trials and a strong pipeline. Although there are risks associated with being a clinical-stage company, Ocugen's financials and upcoming catalysts make it a strong buy for investors.

Bears say

Ocugen is a biotechnology company with a strong potential for growth due to its focus on innovative gene and cell therapies and vaccines for various diseases. However, the company's exclusivity in the market may be limited due to intense competition in the biotech industry. Additionally, there are financial risks associated with the company's ongoing research and development programs, and the company may need to raise additional funding in the future. The recent debt offering and potential for collaborations may provide some relief, but success cannot be guaranteed. Third-party disruptions, such as changes in FDA regulations, could also impact the success of the company's products. Based on these factors, the fundamental outlook for Ocugen is currently negative.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.